Recombinant Mouse CD354/TREM1 Protein, N-His

Introduction

Recombinant Mouse CD354/TREM1 Protein, also known as Triggering Receptor Expressed on Myeloid Cells 1, is a type I transmembrane protein that belongs to the immunoglobulin superfamily. It is encoded by the TREM1 gene and is primarily expressed on myeloid cells, including monocytes, macrophages, and neutrophils. This protein has been extensively studied for its role in regulating the immune response and its potential as a therapeutic target for various inflammatory diseases.

Structure

The Recombinant Mouse CD354/TREM1 Protein is a 227 amino acid long protein with a predicted molecular weight of approximately 25 kDa. It consists of a single extracellular immunoglobulin-like domain, a transmembrane region, and a short cytoplasmic tail. The extracellular domain contains a conserved charged residue that is critical for its binding to its ligand, and the cytoplasmic tail contains a conserved tyrosine residue that is important for signaling.

Activity

Recombinant Mouse CD354/TREM1 Protein is a potent amplifier of the inflammatory response. It is activated upon binding to its ligand, which can be either bacterial or host-derived. This binding triggers a signaling cascade that leads to the production of pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, as well as chemokines, such as IL-8. These molecules play a crucial role in recruiting and activating immune cells to the site of infection or tissue damage.

In addition to its role in inflammation, Recombinant Mouse CD354/TREM1 Protein has also been shown to have a role in sepsis and septic shock. Studies have demonstrated that TREM1 is upregulated in patients with sepsis and that its blockade can improve survival in animal models of sepsis. This further highlights the importance of this protein in regulating the immune response and its potential as a therapeutic target.

Application

Recombinant Mouse CD354/TREM1 Protein has various applications in both research and clinical settings. It is commonly used in in vitro studies to investigate the role of TREM1 in different disease states, such as sepsis, inflammatory bowel disease, and rheumatoid arthritis. It is also used in preclinical studies to evaluate the efficacy of TREM1-targeted therapeutics.

In addition, Recombinant Mouse CD354/TREM1 Protein has potential clinical applications as a biomarker and therapeutic target. Its expression levels have been correlated with disease severity in various inflammatory conditions, making it a potential biomarker for disease diagnosis and prognosis. Furthermore, several TREM1-targeted therapies are currently being developed for the treatment of sepsis and other inflammatory diseases, highlighting the potential of this protein as a therapeutic target.

Conclusion

In conclusion, Recombinant Mouse CD354/TREM1 Protein is a key player in regulating the immune response and has potential applications in both research and clinical settings. Its structure, activity, and potential applications make it a promising target for the development of novel therapeutics for various inflammatory diseases. Further research on this protein is essential for a better understanding of its role in disease pathogenesis and for the development of effective treatments.

ProteoGenix catalogue number ARO-P10459. For research use only.

Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 14.99 kDa; Fragment: Glu26-Lys135; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet